Fig. 1: Clinical presentation and genetic features of patients with iMCD-TAFRO.

Figure 1. Planned intensity and duration of each individual session (ie, dose) and schedule of treatment dose across the study intervention period for linear dosing and nonlinear dosing.

Fig 1. Relative rank ordering of freelisting items (n = 65).

Fig 3. Schematic of skin surface co-registration.

Graphical Abstract.

Figure 1: Genomic alterations in sRCCs by targeted panel sequencing.

Graphical Abstract.

Fig. 1. Study design. LAN–PRRT, lanreotide autogel/depot combined with peptide receptor radionuclide therapy.

Fig. 4: CD36 deficiency stimulates apoptosis in intratumoral Treg cells.

Fig. 4: Monocytes do not persist in the peri-infarct area.

Figure 2: Mathematical modeling predicts optimal treatment schedule.

Figure 1. MRI imaging

Fig. 1. Synthesis and size characterization of fluorescent protein nanoparticles.

Fig 1. Estimated absolute risk of developing breast cancer for women with germline PALB2 pathogenic variants (PVs) by age

Table 2. Results of the 2 rounds of rating.

Fig 3. Bone marrow aspirate smears from patients with chromothripsis-negative AML-MRC revealed a typical myeloid blast morphology (Giemsa, ×1000).

Fig 7. Model of oncogenic splicing factor mutation-induced altered splicing and aberrant NMD.

Fig 1. All-cause cumulative mortality more than 5 years from cancer diagnosis for cancer survivors

Fig 3. DFS (A) and OS (B) for the entire cohort stratified by TMB using a binary cutoff of 2.8 (third quartile). OS by TMB in patients with fusion-negative RMS (C); fusion-positive RMS (D); localized RMS (low/intermediate risk; E); and metastatic RMS (high risk; F).

Figure 1. Brief summary of key clinical trials for programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) blockade.

Abstract. Clearing agents (CAs) can rapidly remove nonlocalized targeting biomolecules from circulation for hepatic catabolism, thereby enhancing the therapeutic index (TI), especially for blood (marrow), of the subsequently administered radioisotope in any multistep pretargeting strategy.